Clinical Pharmacokinetics
https://doi.org/10.1007/s40262-019-00774-0

REVIEW ARTICLE

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update

Elise J. Smolders1,2, Anouk M. E. Jansen1 · Peter G. J. ter Horst1 · Jürgen Rockstroh3 · David J. Back4 · David M. Burger2

© The Author(s) 2019

Abstract

It has been estimated by the World Health Organization (WHO) that over 71 million people were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly effective direct-acting antiviral (DAA) regimens have been licensed for the treatment of chronic HCV infection: sofosbuvir/daclatasvir, sofosbuvir/ledipasvir, elbasvir/grazoprevir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, and sofosbuvir/velpatasvir/voxilaprevir. With these treatment regimens, almost all chronic HCV-infected patients, even including prior DAA failures, can be treated effectively and safely. It is therefore likely that further development of DAAs will be limited. In this descriptive review we provide an overview of the clinical pharmacokinetic characteristics of currently available DAAs by describing their absorption, distribution, metabolism, and excretion. Potential drug–drug interactions with the DAAs are briefly discussed. Furthermore, we summarize what is known about the pharmacodynamics of the DAAs in terms of efficacy and safety. We briefly discuss the relationship between the pharmacokinetics of the DAAs and efficacy or toxicity in special populations, such as hard to cure patients and patients with liver cirrhosis, liver transplantation, renal impairment, hepatitis B virus or HIV co-infection, bleeding disorders, and children. The aim of this overview is to educate/update prescribers and pharmacists so that they are able to safely and effectively treat HCV-infected patients even in the presence of underlying co-infections or co-morbidities.

Key Points

The currently approved direct-acting antivirals (DAAs) can be used to treat a great majority of hepatitis C-infected patients.

Some of the last remaining issues regarding DAA therapy are how to treat patients who have not responded to DAA therapy who have severe resistance associated-substitution, how to manage drug interactions with strong enzyme inducers, and how to treat patients with both decompensated cirrhosis and renal impairment.

Electronic supplementary material

The online version of this article (https://doi.org/10.1007/s40262-019-00774-0) contains supplementary material, which is available to authorized users.

1 Introduction

Hepatitis C virus (HCV) infection is caused by a virus that replicates in the liver; this leads to scarring of the liver which can result in liver diseases such as cirrhosis and hepatocellular carcinoma. In 2015, it was estimated by the World Health Organization (WHO) that over 71 million people were infected with HCV (HCV-RNA positive) [1]. In addition, from 1988 to 2009, 59% of liver transplantations were caused by cirrhosis, of which 40% were virus related [2].

HCV is an RNA virus that can be divided in six genotypes with several subtypes. Recently, a case report of a seventh HCV genotype has been described [3]. Treatment
success and development of liver disease differs per genotype. Another important aspect is the high replication rate and the error-prone nature of the HCV viral replication cycles. This results in a high prevalence of resistance-associated substitutions (RASs), which can occur with and without drug pressure [4].

The landscape of HCV therapy dramatically changed from 2015 onwards. Before 2015, the treatment of HCV was mainly with peg-interferon (peg-IFN) plus ribavirin (RBV) therapy, which was associated with suboptimal response rates and considerable short- and long-term toxicity. HCV cure rates markedly improved with the approval of boceprevir and telaprevir, the first direct-acting antivirals (DAAs), but toxicity was still high [5]. Since the approval of these drugs, several other DAAs have been licensed, with a further increase in response rates for the different HCV genotypes and special patient populations. The timeline of DAA development is presented in Fig. 1.

With the recent approval of the highly effective regimens of glecaprevir (GLE)/pibrentasvir (PIB) [6] and sofosbuvir (SOF)/velpatasvir (VEL) [7] with or without voxilaprevir (VOX) [8], more than 95% of chronic HCV-infected patients can be treated successfully and safely. A remaining challenge is drug pricing, which is still limiting HCV treatment access globally. Clinical challenges in HCV treatment only remain in a few special patient groups such as patients with decompensated cirrhosis, renal impairment, and drug–drug interactions (DDIs). Nevertheless, further DAA drug development has seemingly ended, with few DAAs left in the development pipelines of the major drug companies. The drugs licensed today are the regimens that we will use to reach the WHO goals to eliminate and eradicate HCV [1]. To accomplish this, the biggest challenge in resource-rich countries is to identify all patients who are HCV infected and lost from care or those who were never diagnosed. For the low-income countries, the availability of these drugs is often a major issue because of high pricing.

The aim of this descriptive review is to give an overview of the pharmacokinetics and pharmacodynamics (safety and efficacy) of the DAAs currently used for chronic HCV treatment. In addition, special populations are identified and separately discussed.

## 2 Methods

All phase II and III studies describing efficacy and/or safety of the following DAA combinations were selected for this review: SOF/daclatasvir (DCV); SOF/ledipasvir (LDV); elbasvir (EBR)/grazoprevir (GZR); SOF/VEL; GLE/PIB; and SOF/VEL/VOX. Boceprevir, telaprevir, simeprevir, and paritaprevir/ritonavir, ombitasvir, dasabuvir are not discussed as they have been withdrawn (licensed not extended) from the market and no generic versions of these DAAs will be produced. Retrospective studies and case reports/series were excluded. In addition, the Summaries of Product Characteristics (SmPCs) published by the European Medicines Agency (EMA), the prescribing information published by the US Food and Drug Administration (FDA), and poster presentations available online were used.

The overview of the search terms and results can be found in the Electronic Supplementary Material (ESM) (Table S1), as well as the summary of the efficacy and safety data found in the studies (ESM Table S3–S8).

## 3 Pharmacokinetics

Table 1 presents a summary of the product and dosing information of the DAAs approved by the FDA and EMA. Table 2 provides an overview of the pharmacokinetic parameters of the DAAs.

### 3.1 Daclatasvir (DCV)

#### 3.1.1 Absorption

DCV is readily absorbed as the time to maximal plasma concentration ($t_{max}$) is 1–2 h. The maximal plasma concentration ($C_{max}$), area under the concentration–time curve (AUC), and minimal plasma concentration ($C_{min}$) increase in a dose-proportional matter. Exposure was comparable in HCV-infected patients and healthy volunteers after a dosage of 60 mg [9, 10]. A high-fat meal (950 kcal; 492 kcal fat, 312 kcal carbohydrates, 144 kcal protein) decreases absorption as both the $C_{max}$ and AUC decreased (28% and 23%,
respectively). No effect on absorption of a low-fat meal was observed (277 kcal; 42 kcal fat, 190 kcal carbohydrates, and 44 kcal proteins). In vitro data have shown that DCV is a substrate of the transporter P-glycoprotein (P-gp) (Caco-2 cells) and the absolute bioavailability is 67% [10].

DCV is combined with SOF (Sovaldi®). SOF is quickly absorbed and the median $C_{\text{max}}$ was found after ~ 0.5–2 h. GS-331007 is the main circulating metabolite of SOF and frequently used to describe the pharmacokinetics of SOF. The $C_{\text{max}}$ of GS-331007 was found 2–4 h after administration. The exposure of SOF and GS-331007 were 57% higher and 39% lower when HCV-infected subjects were compared with healthy volunteers. Food increased SOF absorption by a factor of 1.8; however, there were no clinically relevant

### Table 1 Summary of product and dosing information for the direct-acting antivirals approved by the US Food and Drug Administration and European Medicines Agency

| Drug | Brand name | Pharmaceutical form | Dose | Genotypes | Remarks | References |
|------|------------|----------------------|------|-----------|---------|------------|
| Daclatasvir | Daklinza® | Film-coated tablet | 60 mg qd | 1a, 1b, 2, 3, 4 | Available in tablets of 30, 60, and 90 mg | [9, 10] |
| Sofosbuvir/ledipasvir | Harvoni® | Film-coated tablet | 400 mg/90 mg qd | 1a, 1b, 4, 5, 6 | | [15, 16] |
| Elbasvir/grazoprevir | Zepatier® | Film-coated tablet | 50 mg/100 mg qd | 1a, 1b, 4 | | [17, 18] |
| Sofosbuvir/velpatasvir | Epclusa® | Film-coated tablet | 400 mg/100 mg | 1a, 1b, 2, 3, 4, 5, 6 | | [7, 19] |
| Glecaprevir/pibrentasvir | Maviret®/Mavyret® | Film-coated tablet | 100 mg/40 mg qd | 1a, 1b, 2, 3, 4, 5, 6 | | [6, 20] |
| Sofosbuvir/velpatasvir/voxilaprevir | Vosevi® | Film-coated tablet | 400 mg/100 mg/100 mg | 1a, 1b, 2, 3, 4, 5, 6 | | [8, 21] |

$qd$ once daily

### Table 2 Summary of pharmacokinetic parameters for the direct-acting antivirals approved by the US Food and Drug Administration and European Medicines Agency

| Drug | $t_{\text{max}}$ (h) | $C_{\text{max}}$ (ng/mL) | $C_{\text{min}}$ (ng/mL) | AUC (ng·h/mL) | $V_d/F$ | $t_{1/2}$ (h) | Protein binding (%) | References |
|------|---------------------|-------------------------|-------------------------|--------------|---------|-------------|-------------------|------------|
| Protease inhibitors | | | | | | | | |
| Glecaprevir | 5.0 | 597 | NR | 4800 | NR | 6–9 | 97 | [6, 20] |
| Grazoprevir | 2 | 165 | 18.0 | 1420 | 1250 | 24 | > 98.8 | [17, 18] |
| Voxilaprevir | 4 | 192 | 47 | 2577 | NR | 33 | > 99 | [8, 21] |
| NS5A inhibitors | | | | | | | | |
| Daclatasvir | 1–2 | 1534 | 232 | 14,122 | 47 | 12–15 | ± 99 | [9, 10] |
| Elbasvir | 3 | 121 | 48.4 | 1920 | 680 | 31 | > 99.9 | [17, 18] |
| Ledipasvir | 4.0 | 323 | NR | 7290 | 47 | > 99.8 | [15, 16] |
| Pibrentasvir | 5.0 | 110 | NR | 1430 | NR | 23–29 | > 99.9 | [6, 20] |
| Velpatasvir (Epclusa®) | 3 | 259 | 51 | 2970 | NR | 15 | > 99.5 | [7, 19] |
| Velpatasvir (Vosevi®) | 4 | 311 | NR | 4041 | NR | 17 | > 99 | [8, 21] |
| NS5B inhibitors | | | | | | | | |
| Sofosbuvir/GS-331007 (Sovaldi®) | 0.5–2/2 | NR | NR | 1010/7200 | NR | 0.4/27 | 61–65/minimal | [11, 12] |
| Sofosbuvir/GS-331007 (Harvoni®) | ~ 1/4 | 618/707 | NR | 1320/12,000 | NR | 0.5/27 | 61–65/minimal | [15, 16] |
| Sofosbuvir/GS-331007 (Epclusa®) | 0.5–1/3 | 566/868 | NR | 1260/13,970 | NR | 0.5/25 | 61–65/minimal | [7, 19] |
| Sofosbuvir/GS-331007 (Vosevi®) | 2/4 | 678/744 | NR | 1665/12,834 | NR | 0.5/29 | 61–65/minimal | [8, 21] |

Primary data were used from the SmPC and FDA prescribing information concerning HCV-infected patients without cirrhosis. $AUC$ area under the concentration–time curve, $C_{\text{max}}$ maximal plasma concentration, $C_{\text{min}}$ minimal plasma concentration, FDA US Food and Drug Administration, NR data were not reported and/or available in the SmPC and FDA prescribing information, SmPC Summary of Product Characteristics, $t_{1/2}$ elimination half-life, $t_{\text{max}}$ time to maximal plasma concentration, $V_d/F$ volume of distribution
alterations in $C_{\text{max}}$. GS-331007 was not affected by food. The
AUC of SOF and GS-331007 show a near dose-proportional
increase in the range of 200–1200 mg. SOF is a substrate
of the transporters P-gp and breast cancer resistance protein
(BCRP). This is not the case for GS-331007 [11, 12].

### 3.1.2 Distribution

DCV is highly bound to plasma proteins (~ 99%) and the
apparent volume of distribution ($V_d$/L) is 47.1 L. DCV is
passively and actively transported into hepatocytes. In vitro
data have shown that DCV is actively transported by organic
cation transporter (OCT) 1 and inhibits P-gp, organic anion
transporting protein (OATP) 1B1, and BCRP. DCV also
in vitro inhibits the renal transporters organic anion trans-
porter (OAT) 1, OAT3, and OCT2 [9, 10]. OCT2 inhibition
by DCV is not clinically relevant, as shown in a drug interac-
tion study with metformin (an OCT1 and OCT2 substrate)
[13].

SOF is 61–65% bound to plasma proteins and the binding
of SOF is independent of drug concentrations (1–20 µg/mL).
GS-331007 is minimally bound to plasma proteins [11, 12].

### 3.1.3 Metabolism

DCV is a substrate of cytochrome P450 (CYP) 3A4; how-
ever, 97% of the circulating drug is the parent drug and < 5%
of metabolites are found in plasma [9, 10].

SOF has a more complex metabolism (see Fig. 2) [14].
SOF is initially metabolized in the liver into the pharmaco-
logically active nucleoside analog triphosphate GS-461203.
This is followed by dephosphorylation to the main inactive
metabolite GS-331007. GS-331007 accounts for over 90% of
the systemic exposure. SOF only accounts for 4% of the
systemic exposure [11, 12].

### 3.1.4 Excretion

DCV is primarily hepatically cleared, as 88% of a radioac-
tive test dose was retrieved in the feces, of which 53% was
the parent drug. Only 6.6% of the parent drug was excreted
in the urine. The elimination half-life ($t_{1/2}$) is 12–15 h and the
clearance is 4.24 L/h [9, 10].

For SOF, the main route of excretion is via urine (80%);
only 14% of a radioactive dose was recovered in feces. The
majority was retrieved as GS-331007 (78%) and only 3.5%
was recovered as the parent drug. The median $t_{1/2}$ was 0.4 h for SOF and 27 h for GS-331007 [11, 12].

### 3.2 Sofosbuvir (SOF)/Ledipasvir (LDV)

When interpreting the SOF pharmacokinetic data it is important to recognize that the different formulations (e.g., Sovaldi®, Harvoni®, Epclusa®, Vosevi®) all have their own pharmacokinetic profiles and therefore there are slight differences in the described parameters within this review. See also Table 2 for a complete overview.

#### 3.2.1 Absorption

The pharmacokinetics of the fixed-dose tablet SOF/LDV (Harvoni®) are described in this section. The LDV $C_{max}$ was reached after 4–4.5 h. The $t_{max}$ of SOF was ~1 h after drug intake. The main inactive metabolite of SOF, GS-331007 (see Sect. 3.2.3) had a $t_{max}$ of 4 h. The exposure of both GS-331007 and LDV were comparable between healthy volunteers and HCV-infected patients. The exposure of LDV and GS-331007 are not affected by moderate- (600 kcal; 30% fat) and high- (1000 kcal; 50% fat) fat meals. However, the AUC from time zero to infinity (AUC $\infty$) of SOF when taken with food was increased ~2-fold but the $C_{max}$ of SOF was not affected [15, 16]. Despite these differences, response rates with and without food are comparable so SOF/LDV can be administered with or without food [16]. In addition, the solubility of LDV decreases with an increase of pH. Lastly, both SOF and LDV are substrates of the drug transporters P-gp and BCRP [15, 16].

#### 3.2.2 Distribution

LDV and SOF are both bound to plasma proteins: >99.8% and 61–65%, respectively. GS-331007 is not bound to plasma proteins. LDV is an inhibitor of the intestinal transporters P-gp and BCRP. In addition, OATP1B1/2 and bile salt export pump are inhibited [15, 16].

#### 3.2.3 Metabolism

The metabolism of LDV is unknown, but is expected to be minimal as >98% of the parent drug is responsible for systemic exposure [15, 16].

SOF has a more complex metabolism (see Fig. 2 and Sect. 3.1.3) [14]. SOF is metabolized in the liver into the pharmacologically active nucleoside analog triphosphate GS-461203. Dephosphorylation results in the main inactive metabolite, GS-331007. GS-331007 accounts for over 90% of the systemic exposure [15, 16].

#### 3.2.4 Excretion

After a radioactive dose of LDV, 87% of the parent drug was retrieved in urine and feces, of which 86% was in feces. The median $t_{1/2}$ was 47 h [15, 16].

For SOF the main route of excretion is via urine (80%); only 14% of a radioactive dose was recovered in feces. The majority was retrieved as GS-331007 (78%) and only 3.5% was found as the parent drug. The median $t_{1/2}$ was 0.5 h for SOF and 27 h for GS-331007 [15, 16].

### 3.3 Elbasvir (EBR)/Grazoprevir (GZR)

#### 3.3.1 Absorption

The median $t_{max}$ of EBR is 3 h (range 3–6 h) and the estimated bioavailability is ~32%. A high-fat meal (900 kcal; 500 kcal fat) increased absorption (AUC 11% and $C_{max}$ 15%). EBR is a substrate of P-gp.

The median $t_{max}$ for GZR is 2 h (range 0.5–3 h) and the absolute bioavailability after a single dose varied from 15% to 27% and after multiple doses from 20 to 40%. A high-fat meal (900 kcal; 500 kcal fat) increased absorption (AUC 50% and $C_{max}$ 108%). When compared with healthy individuals, HCV-infected patients had increased exposure (~2-fold). GZR is a substrate of P-gp. Steady state is reached around the sixth day of administration [17, 18].

#### 3.3.2 Distribution

EBR and GZR are highly bound to both albumin and $\alpha_1$-acid glycoprotein (>99.9% and >98.8%, respectively) [17, 18]. The estimated $V_d/L$ values for EBR and GZR are 680 and 1250 L, respectively. GZR is actively transported by the hepatic transporter OATP1B1/3 [18]. Although EBR inhibits P-gp, it is not clinically relevant as shown in a drug interaction study with digoxin (11% increase of digoxin). Both drugs inhibit BCRP [17, 18].

#### 3.3.3 Metabolism

Both EBR and GZR are substrates of CYP3A4; however, no circulating metabolites were detected in plasma. GZR is a weak inhibitor of CYP3A4 [17, 18].

#### 3.3.4 Excretion

Both EBR and GZR are primary hepatically cleared as >99% of a radioactive dose was retrieved in feces. The apparent $t_{1/2}$ is 24 and 31 h for EBR and GZR, respectively [17, 18].
### 3.4 SOF/Velpatasvir (VEL)

#### 3.4.1 Absorption

The pharmacokinetics of the fixed-dose tablet SOF/VEL (Epclusa<sup>®</sup>) is described in this section.

The SOF $C_{\text{max}}$ was found 0.5–1 h after administration and the GS-331007 $C_{\text{max}}$ was found 3 h after administration. The exposures of SOF and GS-331007 were comparable in healthy volunteers and HCV-infected patients. A moderate- and high-fat meal increased the AUC$_{\infty}$ of SOF by 60% and 78%, respectively. However, the SOF $C_{\text{max}}$ was not affected by food and the GS-331007 AUC$_{\infty}$ was decreased by 25% and 37%, respectively [7, 19].

The median $t_{\text{max}}$ of VEL is 3 h and the AUC and $C_{\text{max}}$ values were 41% and 37% lower in healthy volunteers than in HCV-infected patients. The VEL AUC was increased 34% and 21% after intake of moderate- (600 kcal; 30% fat) and high-fat (800 kcal; 50% fat) meals; the $C_{\text{max}}$ was only increased by 34% and 5%, respectively. In addition, VEL has pH-dependent solubility and the solubility (and thus absorption) decreases with increasing pH [7, 19].

#### 3.4.2 Distribution

VEL is highly protein bound (> 99.5%), which is independent of the concentration range of 0.09–1.8 µg/mL. SOF is a substrate of P-gp and BCRP and VEL is a substrate of P-gp, OATP1B, and BCRP [7, 19]. SOF is bound 61–65% to plasma proteins, which is dose independent (1–20 µg/mL) [7, 19].

#### 3.4.3 Metabolism

VEL is metabolized by CYP2B6, CYP2C8, and CYP3A4. However, after a single dose > 98% of the parent drug was found in the blood. VEL is an inhibitor of P-gp, BCRP, and OATP1B1/3 [7, 19].

SOF metabolism is discussed in Sect. 3.1.3.

#### 3.4.4 Excretion

As > 94% of VEL was retrieved in feces and 0.4% in urine, clearance of VEL is mainly hepatic. 77% of VEL was recovered in feces as the parent drug. The $t_{1/2}$ of VEL is around 15 h [7, 19]. SOF is mainly renally excreted (80%) and the majority of the dose found was GS-331007 (78%); only 3.5% was found as SOF. The $t_{1/2}$ of SOF was 0.5 h and for GS-331007 was 25 h [7, 19].

---

### 3.5 Glecaprevir (GLE)/Pibrentasvir (PIB)

#### 3.5.1 Absorption

The $t_{\text{max}}$ of GLE/PIB is approximately 5 h and food increases absorption (both moderate- and high-fat meals). GLE exposure was increased 83–163% and PIB 40–53% when taken with a meal. Both drugs are P-gp substrates [6, 20].

#### 3.5.2 Distribution

GLE and PIB are highly bound to plasma proteins (GLE 97.5%; PIB > 99.9%) and actively transported by BCRP. GLE is also a substrate for the hepatic transporter OATP1B1/3 [6, 20].

#### 3.5.3 Metabolism

GLE is metabolized by CYP3A4 and PIB is not subject to biotransformation. In vivo GLE and PIB weakly inhibit CYP3A4 and uridine 5′-diphospho-glucuronosyltransferase (UGT) 1A1 [6, 20].

#### 3.5.4 Excretion

GLE is primarily hepatically excreted as 92.1% of a radioactive dose was retrieved in feces. The $t_{1/2}$ at steady state is 6–9 h. PIB is also primarily excreted in feces (96.6%) and the $t_{1/2}$ is 23–29 h [6, 20].

### 3.6 SOF/Velpatasvir (VEL)/Voxilaprevir (VOX)

#### 3.6.1 Absorption

The pharmacokinetics of the combination tablet SOF/VEL/VOX (Vosesi<sup>®</sup>) is described in this section. VOX, VEL, and GS-331007 reach $C_{\text{max}}$ after approximately 4 h and SOF after 2 h. Compared with healthy individuals, SOF and GS-331007 pharmacokinetics were not altered in HCV-infected patients. For VEL, the AUC and $C_{\text{max}}$ were 41% and 39% decreased in patients, respectively. For VOX, the AUC and $C_{\text{max}}$ were both elevated by 260% when HCV-infected individuals and healthy volunteers were compared [8, 21].

When taken with food (type of meal not defined), the SOF AUC$_{\infty}$ and $C_{\text{max}}$ increased from 64 to 114% and 9 to 76%, respectively. For GS-331007, the $C_{\text{max}}$ was decreased, ranging from 19 to 35%. For VEL, the AUC$_{\infty}$ and $C_{\text{max}}$ were increased, ranging from 40 to 166% and 37 to 187%, respectively. The VOX AUC and $C_{\text{max}}$ increased, ranging from 112 to 435% and 147 to 680%, respectively. Therefore, it is recommended that SOF/VEL/VOX is taken together with a meal [8, 21].
3.6.2 Distribution

SOF, VEL, and VOX are highly bound to plasma proteins (61–65%, > 99%, and > 99%, respectively). For SOF and VEL this was concentration independent in the ranges of 1–20 and 0.09–1.8 µg/mL, respectively. GS-331007 is not bound to plasma proteins. SOF is a substrate of P-gp and BCRP, VEL is a substrate of P-gp, OATP1B1/3, and BCRP, and VOX is a substrate of P-gp and BCRP [8, 21].

3.6.3 Metabolism

VOX is a CYP3A4 substrate; however, after a single radioactive dose, approximately 91% of the circulating drug was the parent drug. VOX is an inhibitor of P-gp, BCRP, and OATP1B1/3 [8, 21].

See Sects. 3.1.3 and 3.4.3 for the metabolism of SOF and VEL, respectively.

3.6.4 Excretion

SOF is mainly renally excreted (80%) and the majority of the dose was GS-331007 (78%); only 3.5% was found as SOF. The $t_{1/2}$ of SOF was 0.5 h and for GS-331007 this was 29 h [8, 21].

As > 94% of VEL was retrieved in feces and 0.4% in urine, clearance of VEL is mainly hepatic. In feces, 77% of VEL was recovered as the parent drug. The $t_{1/2}$ of VEL is around 17 h [7, 19].

The major route of excretion is biliary, as 94% of VOX was recovered in the feces. After a single dose, almost 40% was found as the parent drug and 22.1% as the metabolite des-[methylcyclopropylsulfonamide]-voxilaprevir and three other metabolites (< 10%) [8, 21].

4 Drug–Drug Interactions

As presented in Fig. 3, most DAAs are substrates and inhibitors of drug transporters and CYP enzymes and, therefore, have the potential for DDIs. In this section the most important classes of drugs with interactions with DAAs are briefly discussed. For more information, and for help in clinical decision-making, we recommend the HEP Drug Interactions website (www.hep-druginteractions.org) [22].

4.1 HIV Drugs

Antiretroviral drugs have a high potential for DDIs due to induction or inhibition of CYP3A and drug transporters. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inducing effects, predominantly on CYP3A4. For example, after coadministration with efavirenz, the EBR and GZR AUC decreased by 54% and 87% [17], respectively, and the VEL AUC by ~ 50% [7]. The preferred NNRTIs for coadministration with GLE/PIB, SOF/VEL, and SOF/VEL/VOX are doravirine and rilpivirine [23, 24]. Concomitant use of DCV with a CYP3A4 inducer, such as efavirenz, etravirine, and nevirapine, requires an increase in dose from 60 to 90 mg due to lower DCV exposure [25].

Boosted protease inhibitors (PIs) are inhibitors of CYP3A, OATP, and P-gp. Concomitant use of CYP3A4 inhibitors, such as atazanavir/ritonavir and cobicistat-boosted regimens, requires a decrease in DCV dose from 60 to 30 mg because of decreased CYP3A4 metabolism resulting in elevated DCV plasma concentrations [26, 27]. Use of GLE/PIB with ritonavir-boosted atazanavir is, however, contraindicated due to extreme elevations in GLE and PIB plasma concentrations. The $C_{\text{min}}$ of GLE and PIB increased 14.0-fold and ~ 1.3-fold, respectively [6]. As all boosted PIs are strong CYP3A4 inhibitors, they are not recommended with the GLE and PIB combination [17, 28].

SOF/VEL may be coadministered with any antiretroviral regimen including the boosted PIs atazanavir, darunavir, and lopinavir (boosted with ritonavir or cobicistat) without dose adjustment as no clinically relevant differences in pharmacokinetics of SOF/VEL were observed [29]. SOF/VEL/VOX with darunavir/ritonavir and atazanavir/ritonavir resulted in a 2.4- and 4.3-fold increase in the VOX AUC, respectively, due to OATP1B, P-gp, and CYP3A inhibition and is therefore not recommended [8]. Pharmacokinetic data with other boosted PIs are lacking, but they are not recommended for use together with SOF/VEL/VOX either.

SOF/LDV increases tenofovir exposure due to inhibition of P-gp. This is particularly relevant when LDV is combined with tenofovir disoproxil fumarate (TDF) because of the high tenofovir plasma concentrations [15, 30]. When combined with tenofovir alafenamide this drug interaction is not clinically relevant due to lower circulating tenofovir concentrations [31]. A comparable increase in the tenofovir plasma concentration is observed when TDF is combined with VEL [7, 8]. This increases the risk of tenofovir-related renal toxicity. Therefore, additional monitoring of renal function is advised.

The integrase inhibitors raltegravir, dolutegravir, and bictegravir have favorable interaction profiles and can be safely combined with DAAs [32]. The exception is cobicistat-boosted [31] elvitegravir as this combination also strongly inhibits CYP3A4 and P-gp.

4.2 Immunosuppressive Drugs

Since HCV is a major cause of cirrhosis, which could result in liver transplantation, immunosuppressant agents are commonly used by HCV-infected patients. Therefore, potential DDIs should be considered when treating these patients with both DAAs and immunosuppressive agents.

△ Adis
The immunosuppressive agent cyclosporine (cyclosporin) is a perpetrator of DDIs as it is a strong inhibitor of OATP1B1. Coadministration with EBR/GZR resulted in a 15-fold increase of the GZR AUC. Higher GZR exposure potentially leads to hepatotoxicity and coadministration is thus not recommended [17]. Similarly, combining cyclosporine 100 mg with GLE resulted in an increased AUC (37%) and the GLE AUC increased by 451% after a dose of 400 mg. Since cyclosporine seemingly has a dose-dependent influence on OATP, a maximum of 100 mg/day is recommended [6]. For VOX, the AUC and $C_{\text{max}}$ increased by 19- and 9.4-fold when combined with cyclosporine, respectively. Therefore, SOF/VEL/VOX is not recommended in subjects using cyclosporine [8]. However, to overcome this drug interaction, therapeutic drug monitoring (TDM) of the DAA could be used when no other DAA treatment options are available.

Tacrolimus is a CYP3A4 substrate and its AUC increased by 43% and 1.45-fold after coadministration with EBR/GZR and GLE/PIB, respectively, due to CYP3A4 inhibition [6, 17]. Additional monitoring or dose alterations may be necessary as tacrolimus has a narrow therapeutic range. This DDI can be overcome by using frequent TDM when starting DAA therapy. We strongly recommend frequent monitoring of the tacrolimus plasma concentration when HCV-infected patients are treated, not only to overcome possible DDIs but also because in patients recovering from an HCV infection the tacrolimus plasma concentration can be altered due to altered CYP3A4 metabolism [33]. Significant pharmacokinetic DDIs are not expected with SOF/DCV, SOF/LDV,
PK and PD Considerations in Viral Hepatitis C Therapy

4.3 Cardiovascular Drugs

DDIs with cardiovascular drugs have been previously discussed in a paper published in this journal [34]. In short, statins (HMG-CoA reductase inhibitors) are substrates for several drug transporters, such as P-gp, BCRP, OATP1B1, and CYP enzymes. Generally, coadministration of statins with DAAs results in an increase of the statin AUC, causing higher risk of toxicities such as myopathies. Therefore, caution is needed, and at least adjustment and close monitoring for statin adverse effects are needed. Given the short treatment duration of HCV therapy (only 8–12 weeks), temporary discontinuation of the lipid-lowering drug may be considered as well.

The antiarrhythmic agent amiodarone causes clinically relevant DDIs with SOF-containing regimens: events of severe bradyarrhythmia occurred after concomitant use of amiodarone and SOF [35–37]. The mechanism behind it, however, remains uncertain [38], although it is thought to reflect a pharmacodynamic interaction enhancing the bradycardic effect of amiodarone. Because of the long and variable $t_{1/2}$ (20–100 days) of amiodarone, the timing of starting or discontinuing amiodarone should be kept in mind as DDIs can have a prolonged effect.

Since all of the new oral anticoagulants (NOACs) are substrates for P-gp, and apixaban and rivaroxaban are also substrates for BCRP and CYP3A, there could be an increased risk of toxicity when these drugs are combined with DAAs. This possibly includes bleeding. For both GLE/PIB and SOF/VEL/VOX, the dabigatran etexilate AUC and $C_{\text{max}}$ values were approximately 2- to 3-fold increased after concomitant use [6, 8]. Pharmacokinetic data after coadministration of anticoagulants with other DAAs are not available, but similar results are expected. Therefore, these drugs should either not be used with DAAs or used with caution and careful monitoring when no other anticoagulant is possible [23].

4.4 Anticonvulsant Drugs

The first-generation anticonvulsant drugs (e.g., carbamazepine, phenytoin, phenobarbital) are strong inducers of CYP3A4 and P-gp. These drugs decrease DAA exposure significantly after coadministration, which could result in decreased virological effectiveness. Accordingly, these drugs are either not recommended or contraindicated with all HCV regimens [23]. If no other antiepileptic treatment is possible, the most optimal anti-HCV therapy seems to be SOF with an increased dose of DCV [39].

4.5 Tuberculosis Drugs

In some parts of the world, for instance Eastern Europe, tuberculosis (TB) disease is a burden among HCV or HIV/HCV co-infected patients. This is mainly caused by the fact that these diseases (including hepatitis B virus [HBV]) are prevalent in the same (vulnerable) groups, such as men who have sex with men, prisoners, people who inject drugs, and immigrants and refugees from high endemic countries [40].

TB disease can be treated with combination therapy, but compliance to therapy is very important due to resistance issues. The first-line drugs for the treatment of TB disease include isoniazid, rifampicin (rifampin), rifabutin, rifapentine, ethambutol, and pyrazinamide [41, 42]. All current DAA regimens are contraindicated with rifampicin, rifabutin, and rifapentine as all these drugs are strong inducers of CYP3A4. For example, the AUCs of both SOF and VEL were decreased with 72% and 82% and the $C_{\text{max}}$ by 77% and 71% when combined with rifampicin 600 mg once daily. Comparable results are found with the other DAAs and it is expected that rifabutin and rifapentine also reduce plasma concentrations in the same manner as they are also strong CYP3A4 inducers. Thus, it is not recommended to treat patients with DAAs combined with rifampicin, rifabutin, or rifapentine (similar to anticonvulsant drugs, as noted in Sect. 3.7.4) [7, 19], making it almost impossible to treat a patient for HCV and TB disease at the same time as rifampicin is the cornerstone of current TB disease treatment [41].

Isoniazid, ethambutol, and pyrazinamide are not expected to have any clinically relevant drug interactions with the DAA regimens as the metabolic pathways do not interfere with each other [22].

4.6 Acid-Reducing Agents

Acid-reducing agents such as proton pump inhibitors (PPIs) and histamine H2-receptor antagonists are drugs that influence gastric pH. Both LDV and VEL have pH-dependent absorption. VEL is a weak base which is insoluble in water (pH 7; 0.003 mg/mL) and solubility increases at pH 2 (> 2 mg/mL) [43]. Clinically, this results in decreased exposure of VEL when combined with PPIs such as omeprazole. When omeprazole (20 mg) was combined with SOF/VEL in fasted subjects, the AUC and $C_{\text{max}}$ of VEL decreased (36% and 37%). The VEL AUC and $C_{\text{max}}$ decreased even more when omeprazole 20 mg once daily (fasted) was taken 12 h before SOF/VEL intake (55% and 57%). The same dose of omeprazole administered 2 h before SOF/VEL, with food, also resulted in decreased AUC and $C_{\text{max}}$ values of 38% and 48%. The most promising results were found when omeprazole 20 mg was taken 4 h after SOF/VEL was taken with
food; the AUC and $C_{\text{max}}$ only dropped 26% and 33% [7, 19]. Our recommendation for VEL is not to combine it with acid-reducing agents except when it is really clinically necessary and the PPI cannot be discontinued. Based on the results mentioned here, we advise use of omeprazole 20 mg once daily and administration of SOF/VEL with food 4 h before the PPI is used. H$_2$-receptor antagonists (famotidine 40 mg twice daily or equivalent) should be taken together with SOF/VEL or separated by at least 12 h.

LDV solubility is also pH dependent as it is slightly soluble at pH 2.3 but practically insoluble at pH 4–7.5 [44]. When SOF/LDV was coadministered with omeprazole 20 mg once daily simultaneously, the AUC and $C_{\text{max}}$ were decreased by 4% and 11%. When the intake was separated by 2 h, the LDV AUC and $C_{\text{max}}$ were decreased by 42% and 48% [15, 16]. As for VEL, we do not recommend SOF/LDV be combined with high-dose acid-reducing agents. However, if necessary it can be combined with omeprazole 20 mg once daily or famotidine 40 mg twice daily if taken at the same time as SOF/LDV. It is important to note that these recommendations are based on pharmacokinetic changes of the DAAs and not on efficacy endpoints.

## 5 Efficacy and Toxicity

In this section the pharmacokinetic–pharmacodynamic (PK-PD) relationship of the DAAs and the viral inhibition are described. Pharmacodynamics is defined as reduction of HCV-RNA virus when a patient is treated with the DAAs. To determine the optimal dose, there is a balance between the effect (HCV-RNA reduction) and toxicity (adverse effects, adverse events [AEs]).

ESM Table S2 provides an overview of the dose–response relationships of the DAAs. For most DAAs the approved dose is one of the highest dosages tested. This shows that all the DAAs were well-tolerated during the dose-finding and PK-PD studies. However, this also means that these dosages are likely in the upper part of the s-curve (plateau) where the effect is maximal (Fig. 4). When these thoughts are translated to, for instance, drug interactions, this helps explain why the LDV + PPI drug interaction is marked from a pharmacokinetic perspective (absorption and exposure decreases) but may not be clinically relevant (since in most patients at least, you are still in the upper part of the PK-PD curve with no effect on SVR). It is also important when interpreting these PK-PD relationships to note that there is always variability between individual patients (inter-subject variation). This variation could have several causes such as physiology (age, sex), genetic factors influencing metabolism (e.g., CYP polymorphisms) and drug transport (e.g., OCT or OATP polymorphisms), or environmental factors (smoking, nutrition, alcohol use).

---

**Fig. 4** Pharmacodynamic–pharmacokinetic relationship and factors influencing pharmacodynamics and pharmacokinetics. Every drug has a pharmacodynamic (= effect and toxicity) and pharmacokinetic (= exposure) relationship.
PK and PD Considerations in Viral Hepatitis C Therapy

5.1 SOF/DCV

5.1.1 Efficacy

The combination of SOF/DCV is licensed to treat patients with all HCV genotypes; however, DCV is mostly used to treat HCV in patients infected with HCV genotypes 1, 2, 3, and 4 [23]. In a dose-finding study, DCV was administered in doses of 1, 10, 30, 60, and 100 mg once daily. Geometric mean AUCs showed dose-proportional pharmacokinetics. After 1 day of dosing, the HCV-RNA was decreased by ~ 3 log_{10} IU/mL for all study groups (except 1 mg). The exposure–response analysis suggested a dose varying from 3 to 60 mg once daily [45].

Similarly, single and multiple doses of SOF 50, 100, 200, and 400 mg once daily were administered to HCV genotype 1-infected patients for 3 days. The decline in HCV-RNA viral load was dose dependent and for 400 mg a HCV-RNA reduction of ~ 2 log_{10} IU/mL was seen (200 mg ~ 1 log_{10} IU/mL) [46].

Due to good results in phase II studies, SOF/DCV received early approval. These data are not described in this review as it mainly consists of data in combination with peg-IFN and RBV. Later on, efficacy and safety were studied to a greater extent. The ANRS (France REcherche Nord&Sud Sida-hiv Hépatites) CO22 HEPATHER trial included DAA-naïve HCV genotype 1-infected patients with and without cirrhosis. Overall, 92–99% of the patients achieved sustained virological response (SVR) 12 weeks after treatment (SVR12). The SVR12 rates were 98% and 94% in those without and with cirrhosis, respectively [47]. In a real-world study in DAA-naïve HCV genotype 2-infected patients with and without cirrhosis, all 32 (100%) reached SVR12 [48]. In the ALLY-3 study (phase III), the overall SVR12 rate in HCV genotype 3-infected patients was 89%. Patients with and without cirrhosis yielded SVR12 rates of 63% and 96%, respectively. So, SOF/DCV is not the ideal regimen for HCV genotype 3-infected patients with cirrhosis [49]. Another study showed that patients with advanced fibrosis or compensated cirrhosis obtained an overall SVR12 rate of 90%: 88% and 92% following 12 and 16 weeks of treatment, respectively [50]. HCV genotype 4-infected patients yielded SVR12 rates of 92% in patients with cirrhosis or treatment-experienced patients without cirrhosis [51] (see ESM Table S3).

5.1.2 Toxicity

The most commonly reported adverse effects for the SOF/DCV combination were fatigue, headache, and gastrointestinal complaints such as diarrhea and nausea. In several studies, concomitant therapy with RBV resulted, as previously described [52], in anemia and leukopenia [47, 51, 53–57]. Following an AE, ≤ 7% of the patients discontinued treatment with SOF/DCV, with the exception of patients with a life expectancy of less than 12 months due to decompensated cirrhosis or recurrence of HCV following a liver transplant, in whom 10% and 18%, respectively, discontinued therapy due to an AE [54].

5.2 SOF/LDV

5.2.1 Efficacy

A dose-ranging study using LDV 1, 3, 10, 30, and 90 mg for the duration of 3 days was performed in HCV-infected subjects. On day 3, the AUC during a dosing interval (AUC_t) varied from 34.0 to 3815.5 ng/mL for these dose ranges, showing dose-proportional pharmacokinetics. For all doses the median HCV-RNA reduction was > 3 log_{10} IU/mL, showing comparable viral suppression over the dose range. In the same study the exposure–response relationship of LDV was simulated. The AUC and maximal HCV-RNA decline were used and for genotype 1a patients it was found that a dose of 30 mg would be optimal to have a >95% antiviral response [58]. However, no formal dose/concentration–effect relationship has been established for the combination of SOF plus LDV.

SOF/LDV is an effective treatment in the dose of 90 mg/400 mg once daily. The regimen can be used in patients infected with HCV genotypes 1a, 1b, 4, 5, and 6 (12 weeks) in treatment-naïve patients with or without compensated (Child–Pugh [CP] score A) cirrhosis. Additionally, SOF/LDV (12 weeks) is also effective in treatment-experienced HCV genotype 1b-infected patients [23]. In patients with an HCV-RNA viral load of <6,000,000 IU/mL, the SOF/LDV treatment duration can be decreased to 8 weeks when patients are infected with genotype 1b [59, 60]. Boerekamps et al. [61] even showed that 8 weeks of SOF/LDV can be used to treat both HCV and HIV/HCV co-infected patients with genotype 4-infected patients. The efficacy and safety of SOF/LDV were studied in the ION-1 study, where treatment-naïve HCV genotype 1a-infected patients yielded SVR12 in 99% of individuals after 12 weeks of treatment without RBV. In patients with HCV genotype 1b infection, SVR12 rates of 100% were obtained after the same treatment regimen [62]. In the ION-2 study, 94% of treatment-experienced HCV genotype 1-infected patients, including those with cirrhosis, achieved SVR12 [63]. In a phase III study, treatment-naïve and treatment-experienced patients infected with HCV genotype 1 were treated for 12 weeks without RBV: 100% achieved SVR12, including those with compensated cirrhosis [64]. After 12 weeks of therapy with SOF/LDV, 95% of HCV genotype 4-infected patients achieved SVR12 in the SYNERGY trial [65]. Results were confirmed with SVR12 rates of 96% in treatment-naïve and...
91% in treatment-experienced patients with HCV genotype 4 [66]. HCV genotype 5-infected patients were treated in an open-label phase II study, in which 95% achieved SVR [67]. SVR rates of 64% and 96% were achieved in patients with HCV genotypes 3 and 6, respectively, in an open-label study [68]. In conclusion, the regimen containing LDV and SOF is effective in patients with genotypes 1, 4, 5, and 6 and has reduced efficacy to HCV genotype 3 (ESM Table S4).

5.2.2 Toxicity

The most frequently occurring AEs reported from studies with SOF/LDV were mild, being fatigue, headache, and nausea. In multiple studies no adverse effects at all were reported to occur in over 10% of the study population [69–71]. Less than 5% of the patients discontinued treatment due to an AE in all studies.

5.3 EBR/GZR

5.3.1 Efficacy

EBR/GZR is an effective regimen when used for 12 weeks against HCV genotypes 1 and 4. It is approved for patients with renal insufficiency and compensated cirrhosis [23]. In a dose-finding study, patients with HCV genotype 1 or 3 infection were treated with EBR (5–100 mg) for 5 days and GZR (10–800 mg) for 7 days (both monotherapy). For HCV genotype 1-infected patients treated with GZR with doses > 30 mg, the mean maximum HCV-RNA reduction was > 4.0 \log_{10} IU/mL. For HCV genotype 3, this amount of HCV-RNA reduction was achieved following doses > 400 mg. These data suggest that for GZR the dose–response plateau is reached at a dose of 50 mg once daily; however, this cannot be confirmed for HCV genotype 3-infected patients. For genotypes 1a and 1b the mean maximum HCV-RNA reduction was > 4.0 \log_{10} IU/mL at a dose of EBR 50 mg. For genotype 3 the doses of EBR 50 and 100 mg had a mean maximum HCV-RNA reduction of > 3.0 \log_{10} IU/mL. These data suggest a dose of 50 mg of EBR is sufficient [72].

The combination of EBR/GZR is approved in the fixed-dose combination of 50 mg/100 mg once daily for genotypes 1 and 4. In the C-WORTHY trial, HCV genotype 1-infected patients were effectively treated (with or without cirrhosis, 12–18 weeks) and SVR12 rates varied from 91 to 100% [73]. C-CORAL (treatment-naïve ± cirrhosis) showed SVR12 of 94% in patients with genotypes 1, 4, or 6 [74]. Jacobson et al. [75] performed an integrated analysis showing SVR rates varying from 89 to 100% when treating patients with CP-A (treatment-naïve and treatment-experienced). In addition, genotype 1a patients with HCV-RNA > 800,000 IU/mL had lower SVR rates than genotype 1a patients with HCV-RNA < 800,000 IU/mL (12 weeks: 91% vs. 98%; 16 weeks + RBV: 94% vs. 100%). It was also shown that patients with non-structural protein (NS)5A baseline RASs had an SVR12 of 53% (16/30) after 12 weeks of treatment with EBR/GZR; this was increased to 100% (4/4) when treated for 16 weeks [75]. Therefore, in patients with a high viral load and patients with NS5A RASs, physicians should consider treating for 16 weeks with EBR/GZR.

The C-SALVAGE phase II study was a hypothesis-generating trial to study EBR/GZR + RBV for 12 weeks as a salvage therapy for genotype 1a/1b. Patients who did not respond to a licensed DAA-containing therapy were included, and overall an SVR of 96% was achieved [76].

Low SVR rates were found, varying from 45 to 57%, when treating genotype 3 patients for 12–18 weeks, respectively (C-WORTHY), which fits the previous PK-PD results [77]. Therefore, SOF was added in the C-ISLE trial. This combination was highly effective as SVR12 rates over 94% were reported [78] (ESM Table S5).

5.3.2 Toxicity

Overall, EBR/GZR has a favorable safety profile with low discontinuation rates (≤ 5%). The exception was the ANRS HC34 REVENGE trial where patients with advanced fibrosis or compensated cirrhosis were treated for 24 weeks in combination with RBV, in which 15% (2/13) of the patients discontinued due to AEs [79]. The most frequently reported AEs were fatigue, headache, asthenia, nausea, rash, alanine aminotransferase (ALT)/aspartate aminotransferase (AST) increase, and alkaline phosphatase increase. These increased liver enzymes mostly recovered after treatment with EBR/GZR and are related to the plasma concentration of GZR. The presence of cirrhosis is not a risk factor for this ALT/AST increase [17].

5.4 SOF/VEL

5.4.1 Efficacy

The PK-PD relationship for VEL was established in a dose-ranging study with ascending doses of 5, 25, 50, 100, and 150 mg once daily for 3 days to HCV genotype 1a-infected patients. The reported AUC values after 3 days varied from 86.4 to 5003.0 ng·h/mL for the doses of VEL 5–50 mg, showing dose-proportional pharmacokinetics. For all dose ranges in HCV genotype 1a-infected patients, a maximal HCV-RNA decline of ≥ 3 \log_{10} IU/mL was established. For genotype 3, only the 150 mg dose had a maximal HCV-RNA decline ≥ 3 \log_{10} IU/mL [80].

Treatment with SOF/VEL for 12 weeks is highly effective in both treatment-experienced and treatment-naïve patients with all genotypes of HCV infection. The phase III
ASTRAL-1 trial in patients with HCV genotype 1a, 1b, 2, 4, 5, and 6 infections yielded SVR12 rates varying from 97 to 100% [81]. These results were confirmed by the ASTRAL-2 trial (99% in genotype 2) [82] and multiple real-world studies in patients with all HCV genotypes [83, 84]. ASTRAL-3 showed that patients with genotype 3 infection achieved SVR12 rates of 98% (treatment naïve without cirrhosis). Therefore, this regimen can be used for the treatment of HCV genotype 3-infected patients. However, lower rates were observed in patients with genotype 3 plus cirrhosis or treatment experience (91% and 90%, respectively). All these patients received 12 weeks of SOF/VEL without RBV [82]. Additionally, suboptimal results in HCV genotype 3 patients with compensated cirrhosis were reported (SVR12 78% and 88%, respectively) [85, 86]. For patients with HCV genotype 3 infection and cirrhosis, addition of a third drug to this regimen may be necessary, justifying the triple therapy of SOF/VEL/VOX in this subpopulation (ESM Table S6).

### 5.4.2 Toxicity

The most frequently observed adverse effects from the phases II and III trials of SOF/VEL were headache, fatigue, nausea, and insomnia. As expected, combination therapy with RBV led to anemia in over 10% of the patients in two studies [87, 88]. Discontinuation rates due to an AE were low (≤5%) in all studies.

### 5.5 GLE/PIB

#### 5.5.1 Efficacy

The dose–response relationship of GLE and PIB (both as monotherapy) was assessed in HCV genotype 1-infected patients for 3 days. The GLE dose ranged from 100 to 700 mg and PIB from 15 to 400 mg. Both GLE and PIB have more than dose proportional pharmacokinetics. After a dose of GLE 1200 mg once daily, the AUC was 516-fold higher than with 200 mg once daily. In comparison, PIB 120 mg once daily resulted in a 10-fold increased AUC compared with 30 mg once daily. Both increases are probably caused by saturation of efflux transporters. When PIB is combined with GLE (which is always the case), the exposure is 3-fold higher than with PIB monotherapy [6, 20]. For GLE, the mean maximal decrease in HCV-RNA ranged from 4.1 to 4.3 log_{10} IU/mL. For PIB, HCV-RNA declines of > 3.4 log_{10} IU/mL were seen. The 15 mg dose of PIB resulted in a smaller decline in HCV-RNA than with the doses of 40, 120, and 400 mg [89].

This pan-genotypic regimen is highly effective when administered for 8 or 12 weeks in doses of 100 mg/40 mg once daily (treatment-naïve and treatment-experienced patients, with and without cirrhosis). Multiple phases II and III studies also yielded high rates of SVR12 in patients treated with GLE/PIB in the harder to treat HCV genotypes 1b and 3. In the SURVEYOR phase II study, DAAnaive patients without cirrhosis received GLE/PIB for 8 or 12 weeks and SVR12 rates varied from 97 to 100% [90]. The ENDURANCE studies reported SVR12 rates of 95% in non-cirrhotic patients with HCV genotype 3. Shorter treatment is also possible, as SVR12 rates of 99% and 100% in HCV genotype 1-infected patients without cirrhosis after 8 and 12 weeks of treatment, respectively, were reported [91]. The EXPEDITION-1 trial in HCV genotype 1–6 patients with compensated cirrhosis resulted in SVR12 rates of 99% [92]. In conclusion, GLE/PIB is a pan-genotypic regimen with high efficacy rates in all HCV genotypes, including treatment-experienced patients and those with cirrhosis (ESM Table S7).

#### 5.5.2 Toxicity

In general, GLE/PIB has a mild toxicity profile. The most commonly reported AEs were headache, fatigue, nasopharyngitis, and nausea. Some regimens comprising HCV PIs have been associated with hepatotoxicity (e.g., GZR) [93]. In contrast to these findings, clinically significant laboratory abnormalities for liver function were rare. Elevated ALT, AST, or alkaline phosphatase levels as common AEs were not reported in any of the studies. In addition, increased blood bilirubin and a total bilirubin of more than 1.5–3.0 × the upper limit of normal were reported in only one study [94]. Low rates of discontinuation due to an AE (≤6%) were found with and without concomitant use of RBV in both cirrhotic and non-cirrhotic patients.

### 5.6 SOF/VEL/VOX

#### 5.6.1 Efficacy

The PK-PD relationship of VOX was established in a study in HCV patients infected with all genotypes. Dependent on the genotype, doses of 50–300 mg were administered once daily for 3 days. The AUC_{τ} values at day 3 of administration for all genotypes were 372.3, 1357.6, and 3926.9 ng∙h/mL for the doses of 50, 100, and 300 mg, respectively [95]. This means that VOX has more than dose-proportional pharmacokinetics [21]. For all genotypes, the doses ranging from 100 to 300 mg once daily resulted in a mean maximal HCV-RNA reduction of > 3 log_{10} IU/mL [95].

This pan-genotypic combination is highly effective and licensed to treat patients with and without compensated cirrhosis and patients that previously failed to respond on both peg-IFN/RBV and DAAAs. Phase II studies showed high efficacy in treatment-naïve patients with compensated cirrhosis and all genotypes (including genotype 3). SVR12
rates varied from 93 to 97% in patients with cirrhosis and rates of 88 to 100% without cirrhosis with varying treatment durations of 6–12 weeks were achieved in patients with genotypes 2, 3, 4, or 6 [96]. Therefore, the phase III trials (POLARIS) continued with a treatment duration of 8 and 12 weeks. The POLARIS 2/3 analysis showed an SVR12 rate of 95% after treating a diverse group of 501 patients (treatment-naive, treatment-experienced, with and without compensated cirrhosis) [97].

In the POLARIS 1 trial where, among others, treatment-experienced, HCV genotype 3-infected patients were treated for 12 weeks, an SVR12 rate of 100% was achieved. In the POLARIS 4 study an SVR of 99% was achieved in a comparable group of patients [98]. Taking these results into account, the current recommendation is to treat DAA treatment-experienced and/or compensated cirrhotic patients with this combination for 12 weeks and to treat treatment-naive patients for 8 weeks. However, in our opinion, this regimen should be used as salvage therapy due to the efficacy of double medication regimens (ESM Table S8).

5.6.2 Toxicity

The toxicity profile of this combination regimen is mild. In the different trials the most frequently reported AEs were headache, diarrhea, fatigue, nausea, and constipation. In addition, the discontinuation rate due to AEs was low (≤ 3%) in all trials. As VOX is a PI, this combination should not be used in patients with CP-B/C cirrhosis as exposure increases, which could potentially cause safety issues (see Sect. 5.2).

6 Special Populations

The overall ranges of SVR12 for the combination treatment regimens in different study populations are presented in Table 3.

6.1 Hard to Cure Patients

In the era of DAA therapy, patients with genotype 3, cirrhosis, or who are treatment experienced were initially considered hard to cure (or hard to treat) as SVR rates were lower than with other patient populations. To increase the chance of achieving SVR, RBV was added to the first DAA regimens or treatment durations were extended. In this section we discuss the current treatment options for those patients.

6.1.1 Genotype 3

Genotype 3 patients were easier to cure with peg-IFN/RBV than genotype 1 patients. Nevertheless, response rates were higher with the first approved DAA regimens; however, the SVR rates were lower than with genotype 1 or 4 patients. For example, a real-world study showed an SVR12 rate of 83% in genotype 3 patients with advanced fibrosis treated with SOF/DCV [99]. Additionally, 90% SVR12 was achieved in genotype 3 patients (with advanced fibrosis/compensated cirrhosis) treated with SOF/DCV/RBV for 12–16 weeks [50]. Due to good response rates, the preferred regimens, at this time, are SOF/VEL [82, 84–87, 100–104], GLE/PIB [90, 91, 105–107], or SOF/VEL/VOX [96–98, 108] for at least 12 weeks of treatment. With the currently available pan-genotypic treatment options, there no longer seems to be the need to approach HCV genotype 3-infected patients as hard to cure patients.

6.1.2 Treatment-Experienced Patients

Treatment-experienced patients can be divided into two categories: patients who failed to respond to peg-IFN/RBV and those who failed to respond to DAA therapy. Both groups are considered hard to cure, but DAA-experienced patients are a higher risk due to the appearance of RASs. However, with the current treatment options, these treatment-experienced patients also obtain high SVR12 rates when DAA regimens are used that combine DAAs from the three currently available HCV drug classes.

Importantly, patients previously treated with peg-IFN/RBV without cirrhosis can be treated as ‘normal’ patients. For all treatment regimens the SVR12 rates are up to 100%. The most successful results were achieved with treatment regimens consisting of SOF/DCV [47, 48, 53, 56, 109–114], GLE/PIB [94, 105, 106, 115–117], and SOF/VEL/VOX [96, 98, 108, 118]. Although efficacious, triple combination therapy is not indicated since double treatment regimens are also effective.

Limited data are available for the DAA-experienced patients. Excellent results were obtained in these patients with SOF/VEL/VOX [98] and GLE/PIB also showed good results for re-treatment of patients who previously failed to respond to NS5A inhibitors [116]. In patients with NS5A RASs, triple therapy with either SOF/VEL/VOX or the experimental combination SOF/GLE/PIB could be options [119].

With the DAA regimens currently available, peg-IFN/RBV treatment-experienced patients have numerous options to attain successful virological eradication. The remaining hard to cure population is those patients who have previously
### Table 3 Ranges of sustained virological response 12 weeks after therapy rates for combination treatment regimens in different study populations

| Population/drug | SOF/DCV | SOF/LDV | EBR/GZR | SOF/VEL | GLE/PIB | SOF/VEL/VOX |
|-----------------|---------|---------|---------|---------|---------|-------------|
| **HCV genotype** |         |         |         |         |         |             |
| Genotype 1      |         |         |         |         |         |             |
| Genotype 1a     | 76–97[^a,c] [55, 56, 110, 111, 162] | 96 [125] | 80–100[^a] [74–76, 121–123, 128, 130, 150, 172] | 88–100[^a] [81, 87, 100, 102] | 95–100[^a] [90–92, 115, 116, 154] | 92–98 [97, 98, 155] |
| Genotype 1b     | 88–100[^a] [55, 56, 110, 111, 162] | 96–100[^b] [69, 125, 136, 195] | 91–100[^a] [75, 76, 121, 122, 128, 163] | 89–100[^a] [81, 87, 88, 100, 102] | 96–100 [90, 92, 94] | 97–100 [96–98] |
| Genotype 2      | 67–100[^b] [48, 54, 55, 112] | 74–100[^d] [70, 132, 196] | 77[^a] [197] | 88–100[^a] [81, 82, 85, 87, 88, 100, 102, 104] | 96–100 [90, 92, 94] | 94–100 [96–98, 108] |
| Genotype 3      | 67–100[^b,c] [49, 50, 54–56, 99, 110, 162, 174, 178] | 64–100[^a] [68, 138] | 45–100[^a] [77, 78] | 50–100[^c] [82, 84–87, 100–104] | 83–100[^a] [90, 91, 106, 107, 115] | 80–100[^a] [96–98] |
| Genotype 4      | 90–100[^a] [51, 53, 55–57, 109, 110, 113, 162, 174, 186, 187, 198] | 0–100[^b,c] [65, 66, 124, 125, 144, 146, 185, 199, 200] | 67–100[^b] [74, 75, 121, 122, 128, 130, 150, 172, 197] | 100 [81, 87, 100, 102] | 100 [92] | 80–100 [96–98] |
| Genotype 5      | 100 [110] | 95 [67] | 25–100[^b] [197] | 97 [81] | 100 [92] | 100 [98] |
| Genotype 6      | 100[^a] [55] | 96 [147] | 63–80[^a] [74, 121, 150, 197] | 100 [81] | 100 [92] | 100 [96, 98, 155] |
| **HCV treatment experience** |         |         |         |         |         |             |
| Treatment naïve | 88–100[^a] [47, 49, 51, 53, 56, 111–114, 178, 186, 187, 198, 201] | 64–100[^a] [62, 66–68, 71, 132, 133, 136–138, 143, 188, 191, 194, 195, 199, 200] | 25–100[^a] [73–75, 77, 78, 121, 122, 128, 149, 150, 172, 197] | 93–100 [82, 84, 101, 102] | 96–100 [90, 107, 115, 131] | 80–100[^a] [96, 118] |
| Treatment experienced | 82–100[^a] [47–49, 56, 109–114, 201] | 70–100[^a] [63, 66–68, 71, 126, 132, 133, 135, 136, 143, 145, 147, 173, 188, 191–193, 200] | 67–100[^a] [73, 75, 76, 78, 79, 122, 128] | 78–100[^a] [82, 83, 85, 86, 88, 102, 104, 202] | 83–100[^a] [94, 105–107, 115, 116, 203] | 89–100 [96, 98, 108, 118] |
| **Cirrhosis** |         |         |         |         |         |             |
| Without cirrhosis | 94–100[^a] [47–49, 51, 57, 109, 111, 113, 174, 178, 186, 187, 198, 201, 204] | 75–100[^b] [124, 126, 137, 138, 144, 147, 173, 179, 188, 194] | 25–100[^a] [77, 122, 129, 197] | 91–100 [82, 85, 86, 102, 104] | 91–100[^a] [90, 91, 94, 107, 116, 131, 154] | 100 [96, 118] |
| With cirrhosis | 50–100[^b,c] [47–50, 53–55, 57, 109, 111, 112, 162, 174, 201] | 0–100[^b,c] [65, 67, 71, 124, 126, 135, 138, 142–147, 173, 179, 188] | 90–100[^a] [73, 74, 78, 79, 122, 129] | 50–100[^c] [82, 83, 85, 88, 101–103] | 96–100[^a] [92, 94, 107, 115, 154] | 80–100[^a] [96, 97, 108, 118, 155] |
| **Special populations** |         |         |         |         |         |             |
| Transplant | 67–100[^b] [54, 55, 99, 110, 162] | 50–100[^b] [69, 124, 146, 157] | 96 [104] | 98–100 [131] |         |             |
failed to respond to both PI and NS5A inhibitor-containing regimens, with the possibility of NS5A RASs.

6.1.3 Patients with Resistance-Associated Substitutions

Resistance-associated substitutions (RASs) to DAAs, due to the error-prone nature of the HCV RNA polymerase, may be present at baseline and can significantly affect treatment outcomes and the achievement of SVR [120].

RASs in NS3 may affect virological results in patients treated with an NS3 inhibitor, such as GZR, GLE, and VOX. NS3 RASs at baseline were associated with lower rates of SVR12 after 12 weeks of treatment with EBR/GZR than in HCV-infected patients without this type of RAS [77, 78, 121–123]. This pattern was also observed after treatment with GLE/PIB [91]. On the contrary, in a phase III trial 12 weeks of treatment resulted in SVR12 rates of 100% (6/6) and 92% (34/37) in patients with and without baseline NS3 RASs, respectively [107]. These findings may, however, be a result of small sample sizes. Similar patterns were observed for SOF/VEL/VOX, which implicates that NS3 RASs indeed are associated with lower virological efficacy rates [97, 98].

DCV, EBR, LDV, PBR, and VEL are NS5A inhibitors and are therefore expected to alter SVR rates in subjects with baseline NS5A RASs [55]. Similar results were achieved in studies with SOF/LDV [66, 70, 124–127], EBR/GZR [75, 78, 121–123, 128–130], SOF/VEL [82–84, 86–88, 103], GLE/PIB [91, 107, 131], and SOF/VEL/VOX [97, 98].

Because of its interference with NS5B, a SOF-containing regimen could have decreased efficacy in patients with baseline NS5B RASs. However, this does not seem to be such an issue as it is with the other RASs. Many patients are treated with SOF and only a few incidental reports of these kinds of NS5B RASs are presented. SVR12 rates varied from 88 to 100% with all SOF-containing regimens [66, 70, 82, 84, 104, 126, 130, 132–138].

Although the SVR in patients with baseline RASs is somewhat lower than in those without RASs at baseline, overall rates for efficacy remain high even in this population. Additionally, patients with baseline RASs for one protein have other treatment options in reserve that encounter another HCV protein.

6.2 Liver Cirrhosis

Chronic hepatitis may lead to progressive liver fibrosis and subsequently result in cirrhosis, which could alter the pharmacokinetics and pharmacodynamics of a drug. We have previously described the possible issues with liver cirrhosis in more detail [139].

Total DCV $C_{\text{max}}$ and AUC values were lower in subjects with cirrhosis than in subjects with normal liver function after a single 30 mg dose of DCV. The DCV AUC was 43,
PK and PD Considerations in Viral Hepatitis C Therapy

Not recommended as safety and efficacy not studied in patients with Child–Pugh score B.

Clinical and hepatic laboratory monitoring is indicated with decompensated patients.

Table 4: Dose adjustments in patients with cirrhosis

| Drug                              | Normal dose | Child–Pugh score A | Child–Pugh score B | Child–Pugh score C | References |
|-----------------------------------|-------------|--------------------|--------------------|--------------------|------------|
| Daclatasvir                       | 60 mg qd    | 60 mg qd           | 60 mg qd           | 60 mg qd           | [9, 10]    |
| Sofosbuvir/ledipasvir             | 400 mg/90 mg qd | 400 mg/90 mg qd | 400 mg/90 mg qd | 400 mg/90 mg qd | [15, 16] |
| Elbasvir/grazoprevir              | 50 mg/100 mg qd | 50 mg/100 mg qd | Contraindicate     | Contraindicated    | [17, 18]  |
| Sofosbuvir/velpatasvir            | 400 mg/100 mg qd | 400 mg/100 mg qd | 400 mg/100 mg qd | 400 mg/100 mg qd | [7, 19]   |
| Glecaprevir/pibrentasvir          | 100 mg/40 mg qd | 100 mg/40 mg qd | Not recommended    | Contraindicated    | [6, 20]   |
| Sofosbuvir/velpatasvir/voxilaprev | 400 mg/100 mg/100 mg qd | 400 mg/100 mg/100 mg qd | Not recommended | Not recommended | [8, 21]   |

qd once daily

\(a\) Clinical and hepatic laboratory monitoring is indicated with decompensated patients

\(b\) Not recommended as safety and efficacy not studied in patients with Child–Pugh score B.
promising. Overall, 96–100% of patients achieve SVR12 following 12 weeks of treatment without [92, 105, 107, 154] or with RBV [105]. GLE/PIB is not recommended in patients with decompensated cirrhosis, but may be effective in treating CP-A patients.

No pharmacokinetic studies of the triple combination therapy SOF/VEL/VOX for HCV-infected patients with cirrhosis were performed. Since VOX is a PI, it is expected that it will increase hepatotoxicity and should therefore not be used in patients with decompensated cirrhosis (see Table 4). The treatment regimen was found to be highly effective in patients with CP-A cirrhosis, with SVR12 rates of 80–100% [96, 97, 108, 118, 155]. However, none of these studies included patients with decompensated cirrhosis, which makes implementation to all types of cirrhotic patients difficult.

6.3 Transplant Patients

HCV infection has a negative impact on both patient and graft survival in kidney transplant recipients compared to those without HCV infection [156]. Additionally, DDIs with immunosuppressants also make this population prone to negative treatment outcomes (see Sect. 4.2).

Efficacy and safety have not been studied thoroughly in transplant patients, but, to date, results seem promising that DAA treatment is safe and effective. For kidney transplant recipients, SOF/LDV therapy resulted in an SVR12 of 100% following treatment for 12 or 24 weeks without RBV. No significant changes in estimated glomerular filtration rate (eGFR) were observed during and after treatment [157]. These successful virological results were confirmed in several clinical trials and real-world studies [158–161]. High efficacy rates with favorable safety profiles in kidney transplant recipients were also retrieved with SOF/DCV [159–161] and GLE/PIB [131]. DAA therapy was well-tolerated in all studies, with mild AEs and laboratory abnormalities being infrequent.

Liver transplant recipients with HCV recurrence obtained an SVR rate of 94% following SOF/DCV/RBV for 12 weeks. Similar results were achieved in other studies with liver transplant patients [54, 110, 162]. Efficacy rates for SOF/LDV varying from 50 to 100% were seen in HCV recurrent liver transplant recipients following the fixed-dose combination of SOF/LDV [69, 124, 146]. SVR12 rates lower than 85% were only achieved in studies with low numbers of included patients (n < 10) [124]. Comparably, 12 weeks of treatment with SOF/VEL and GLE/PIB resulted in SVR12 rates of 96% and 89%, respectively, in liver transplant recipients [104, 131]. Therapies were generally well-tolerated with no serious adverse effects, laboratory abnormalities, or graft transplant rejection in relation to the treatment.

In conclusion, DAA therapy seems to be effective and safe in transplant patients with no therapy alterations being necessary.

6.4 Renal Impairment

Two SOF-free regimens are available: EBR/GZR and GLE/PIB. EBR and GZR are both minimally (< 1%) renally excreted; it is therefore not expected that overall clearance of either drug will be affected. After normal doses, EBR/GZR exposure is increased by 50–86% in both advanced chronic kidney disease (CKD) patients with and without HCV infection compared with healthy controls. For patients with end-stage renal disease (ESRD), EBR and GZR exposure was not significantly affected. Also, the steady-state pharmacokinetics of EBR and GZR were not influenced by dialysis [17, 18]. The efficacy and safety of EBR/GZR in patients with renal impairment were studied in multiple trials and SVR12 varied from 94 to 100% in various populations [149, 163–165]. Therefore, this regimen is safe and effective for patients with renal impairment, requiring no dose adjustment (see Table 5).

Renal excretion of both GLE and PIB are minimal (< 4%). For both drugs, the AUC was increased up to 13, 30, 45, and 56% in subjects with mild, moderate, and severe renal impairment or ESRD, respectively, compared with normal subjects [166]. The efficacy and safety of GLE/PIB were studied in patients with severe renal impairment (CKD stage 4 or 5): the SVR12 rate was 98% after treatment with the fixed-dose combination of GLE/PIB for 12 weeks [105]. These results were confirmed with an SVR12 rate of 100% in patients with severe renal dysfunction and prior DAA treatment [106]. This treatment, therefore, is considered to be effective and safe in patients with severe renal insufficiency and no dose adjustments are required (see Table 5).

SOF is mainly renally excreted and reduced clearance can be expected in patients with renal dysfunction [11]. Concerns have risen due to substantially higher concentrations of the primary metabolite of SOF, GS-331007, in these patients (see Fig. 2). Patients with mild, moderate, and severe renal insufficiency obtained increased SOF AUC values of 61, 107, and 171%, respectively, compared with controls. GS-331007 AUC values were elevated by 55, 88, and 451%, respectively, so accumulation could occur [167]. Therefore, SOF-free regimens are generally preferred in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²). In all other patients, restrictions regarding SOF are unnecessary [23].

However, increased exposure of GS-331007 is not associated with increased toxicity [12]. Due to the metabolism of SOF, it makes pharmacological sense to give a full dose of 400 mg to patients with impaired renal function. The reason for this is that we need to achieve high enough active
metabolite (GS-461203) concentrations in the liver for the antiviral action of SOF. Lower doses possibly result in lower active metabolite concentrations and response rates (see Sect. 4). It has been shown that SOF in standard doses is well-tolerated in patients with renal impairment [160, 168, 169] and that alternate dosing of LDV/SOF in hemodialysis patients yielded SVR12 rates of 91% [170]. In patients undergoing dialysis, a 95% SVR12 rate was achieved after SOF/VEL use for 12 weeks. The safety of this combination regimen was consistent with advanced renal disease and was well-tolerated [171]. In case no safer DAA options are available, e.g., in patients with other co-morbidities, treatment with SOF may therefore be acceptable.

### 6.5 Hepatitis C Virus (HCV)/HIV Co-Infection and Hepatitis B Virus/HCV Co-Infection

Historically, HCV/HIV co-infected patients were harder to treat patients, as SVR rates were lower in the peg-IFN/RBV era than in HCV mono-infected patients. However, SVR12 rates after treatment with DAA regimens in HCV/HIV co-infected patients are comparable with HCV mono-infected patients and this is extensively shown in the literature [52, 56, 111, 114, 123, 125, 128, 137, 172–174].

HBV co-infected patients have a potential risk of HBV reactivation during or after HCV clearance, although this remains unpredictable [175]. The efficacy of HCV therapy in HBV/HCV co-infected patients was high (SVR12 100%) with SOF/LDV therapy for 12 weeks. Approximately two-thirds of the patients had an increased HBV DNA level during treatment, although this was not associated with any signs or symptoms. Only 2 of the 111 included patients required HBV therapy during SOF/LDV treatment. No (serious) AEs were reported and no patients discontinued treatment [70]. Based on this study, there seems to be no reason to treat HBV co-infected patients differently to mono-infected patients. Therefore, HBV/HCV co-infected patients should be treated with the same anti-HCV treatment regimens as HCV mono-infected patients, keeping the HBV reactivation in mind—meaning that HBV DNA and ALT flares should be monitored at least every 4–8 weeks and 3 months post treatment according to American Association for the Study of Liver Diseases (AALSD) guidance [176]. Patients that are hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive have a low reactivation risk and ALT should only be monitored at baseline, end of treatment, and during follow-up [176].

### 6.6 Bleeding Disorders

Since treatment with interferon and RBV are associated with anemia, anti-HCV therapy has often been withheld in patients with bleeding disorders. Several phases II and III studies have examined the safety and efficacy of DAA treatment regimens in this special population. Results in patients

---

**Table 5** Dose adjustments in patients with renal impairment

| Drug                          | Normal dose | eGFR 30–50 mL/min | eGFR 10–30 mL/min | eGFR < 10 mL/min | Removed by hemodialysis | References |
|-------------------------------|-------------|-------------------|-------------------|-----------------|-------------------------|------------|
| Daclatasvir                   | 60 mg qd    | 60 mg qd          | 60 mg qd          | 60 mg qd        | Unlikely, high protein binding | [9, 10]    |
| Sofosbuvir/ledipasvir         | 400 mg/90 mg qd | 400 mg/90 mg qd | Not recommendeda | Not recommendeda | Ledipasvir: unlikely GS-331007: yes, 53% | [7, 19]    |
| Elbasvir/grazoprevir          | 50 mg/100 mg qd | 50 mg/100 mg qd | 50 mg/100 mg qd  | 50 mg/100 mg qd | No                      | [15, 16]   |
| Sofosbuvir/velpatasvir        | 400 mg/100 mg qd | 400 mg/100 mg qd | Not recommendeda | Not recommendeda | Velpatasvir: unlikely GS-331007: yes, 53% | [6, 20]    |
| Glecaprevir/pibrentasvir      | 100 mg/40 mg qd | 100 mg/40 mg qd | 100 mg/40 mg qd  | 100 mg/40 mg qd | No                      | [17, 18]   |
| Sofosbuvir/velpatasvir/voxilaprevir | 400 mg/100 mg/100 mg qd | 400 mg/100 mg/100 mg qd | Not recommended | Not recommended | Velpatasvir and voxilaprevir: unlikely GS-331007: yes, 53% | [8, 21]    |

*eGFR* estimated glomerular filtration rate, *qd* once daily

aNot recommended as safety and efficacy has not been studied in patients with eGFR < 30 mL/min

---

△ Adis
with bleeding disorders do not seem to differ from those in patients without these conditions [122, 135, 177–181]. Recommendations for HCV treatment in this special population are therefore equal to those without a bleeding disorder. However, as several RBV-free regimens are available, the preferred option is to treat these patients with the RBV-free regimens of SOF/VEL or GLE/PIB.

### 6.7 Children and Adolescents

Mother-to-child transmission of HCV is the most common source of HCV infection in children; however, treatment of HCV-infected newborns is not yet possible [182, 183]. Therefore, children can be treated (see below) or HCV treatment during pregnancy is an option, not only to cure maternal HCV but also to reduce the incidence of pediatric HCV cases. With the introduction of RBV-free DAA treatment combinations, which are highly effective and show a favorable safety profile in preclinical animal studies, treatment during pregnancy seems realistic in the nearby future [184].

Children and adolescents may require treatment alterations compared with adults due to differences in pharmacokinetics that potentially lead to efficacy and/or safety issues in this population. Administration of half of the adult fixed-dose of SOF/LDV in children (6 to < 12 years) resulted in comparable exposure to that in adults exposed to the fixed-dose combination: the AUC was 13% lower, 16% higher, and 34% lower for LDV, SOF, and GS-331007, respectively. The $C_{max}$ was 16, 39, and 6% higher for these three compounds. An SVR of 99% was achieved in these DAA-naive children with genotypes 1, 3, or 4 HCV infection [134].

Exposure in adolescents (12 to < 18 years) was comparable with that in adults following the adult fixed-dose combination of SOF/LDV: SOF, GS-331007, and LDV AUC, increased by 60, 5, and 27%, respectively, and $C_{max}$ was 56, 39, and 62% higher, respectively [132]. Efficacy was also comparable with that in adults, as all 40 adolescents (treatment-naïve, treatment-experienced, genotype 4) achieved SVR when treated with LDV/SOF [185]. The SVR12 rate was 98% in HCV genotype 1-infected adolescents (12–17 years) with and without compensated cirrhosis [132]. No serious AEs were reported in any of the studies.

Weight-based (≥ 45 kg: 400 mg/60 mg; 17–45 kg: 200 mg/30 mg) SOF/DCV resulted in SVR12 rates of 97% in HCV genotype 4-infected adolescents (12–17 years) [186].

In a study with patients aged 8–18 years, SVR12 was 98% in HCV genotype 2-infected adolescents (treatment-naïve, treatment-experienced, genotype 4) achieved SVR when treated with LDV/SOF [185]. The SVR12 rate was 98% in HCV genotype 1-infected adolescents (12–17 years) with and without compensated cirrhosis [132]. No serious AEs were reported in any of the studies.

Weight-based (≥ 45 kg: 400 mg/60 mg; 17–45 kg: 200 mg/30 mg) SOF/DCV resulted in SVR12 rates of 97% in HCV genotype 4-infected adolescents (12–17 years) [186].

In a study with patients aged 8–18 years, SVR12 was 98% after SOF/DCV 400 mg/60 mg per 1.7 m² [187].

At present, DAA therapy seems to be effective and safe (probably after dose adjustments based on bodyweight) in children and adolescents; however, additional studies may be necessary to confirm these statements.

### 7 Conclusion

In this descriptive review, we have provided an overview of the clinical pharmacokinetics and pharmacodynamics, in terms of efficacy and toxicity, of the DAA combination regimens for the treatment of chronic HCV. Although we have listed all available treatment DAA regimens and options, no differences have been discussed in pricing and/or availability of the regimens. One should consider that in some counties only the pan-genotypic regimens SOF/VEL and GLE/PIB are available as first-line agents. In our opinion, SOF/VEL/VOX should be preserved as the salvage regimen for DAA failures.

We have also discussed the relationship between the pharmacokinetics of the DAAs and efficacy or toxicity in patients with liver cirrhosis, liver transplantation, renal impairment, HBV or HIV co-infection, and bleeding disorders, and in children and adolescents.

As the development of treatments for HCV therapy is thought to have come to an end, this review gives a complete overview of all possible treatment options for chronic hepatitis C in well-resourced countries. This aids in ensuring that making informed decisions in clinical practice is feasible and physicians, pharmacists, and nurse practitioners are educated to effectively and safely treat HCV-infected patients.

**Acknowledgments** We thank Jolien Freriksen and Minou van Seyen, both Ph.D. candidates at the Radboud University Medical Center, for providing information about HCV treatment in pregnant women.

**Compliance with Ethical Standards**

**Conflict of interest** EJS declares having received travel grants from Abbvie and Gilead. AMEJ and PGJTH declare no conflicts of interest that are directly relevant to the content of this review. DMB is on the advisory boards for Gilead and Merck and has received sponsorship/research grants from BMS, Gilead, Janssen, Merck, and Viiv. DIB is on advisory boards for Abbvie, Gilead, and Merck and has received research support/educational grants from Abbvie, Gilead, Janssen, and Merck. JKR has received honoraria for consulting or speaking at educational events from Abbvie, Abivax, Gilead, Janssen, Siemens, Merck, and Viiv. These conflicts of interest did not influence the preparation of this review.

**Funding** No funding was used in the preparation of this review.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. World Health Organization. Hepatitis C fact sheet. 2018. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed 19 Feb 2019.
2. European Association for the Study of the Liver. The burden of liver disease in Europe: a review of available epidemiological data. 2013. http://www.easl.eu/medias/EASLimg/Discover/EU/54ae845caec619f_file.pdf.

3. Schreiber J, McNally J, Chodavarapu K, Svarovskaia E, Moreno C. Treatment of a patient with genotype 7 hepatitis C virus infection with sofosbuvir and velpatasvir. Hepatology. 2016;64(3):983–5.

4. Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016;12(10):1197–209.

5. European Medicines Agency. Summary of product characteristics: Viekira. 2019. https://www.ema.europa.eu/documents/product-information/viekira-epar-product-information_en.pdf. Accessed 2 Feb 2019.

6. European Medicines Agency. Summary of product characteristics: Maviret [in Dutch]. 2019. https://www.ema.europa.eu/documents/product-information/maviret-epar-product-information.nl.pdf. Accessed 2 Feb 2019.

7. European Medicines Agency. Summary of product characteristics: Epclusa [in Dutch]. 2019. https://www.ema.europa.eu/documents/product-information/epclusa-epar-product-information.nl.pdf. Accessed 2 Feb 2019.

8. European Medicines Agency. Summary of product characteristics: Vosevi. 2019. https://www.ema.europa.eu/documents/product-information/vosevi-epar-product-information_en.pdf. Accessed 2 Feb 2019.

9. European Medicines Agency. Summary of product characteristics: Daklinza. 2019. https://www.ema.europa.eu/documents/product-information/daklinza-epar-product-information_en.pdf. Accessed 2 Feb 2019.

10. US Food and Drug Administration. Highlights of prescribing information: Daklinza. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206843s006lbl.pdf. Accessed 19 Feb 2019.

11. European Medicines Agency. Summary of product characteristics: Sovaldi. 2019. https://www.ema.europa.eu/documents/product-information/sovaldi-epar-product-information_en.pdf. Accessed 2 Feb 2019.

12. US Food and Drug Administration. Highlights of prescribing information: Sovaldi. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/204671s002lbl.pdf. Accessed 19 Feb 2019.

13. Smolders EJ, Colbers EP, de Kanter CT, Velthoven-Graafland K, Drenth JP, Burger DM. Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cockistat. J Antimicrob Chemother. 2017;72(2):486–9.

14. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luettekemeyer A, Morgan TR, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–25.

15. Feng HP, Caro L, Fandozzi C, Chu X, Guo Z, Talaty J, et al. Pharmacokinetic interactions between the HCV inhibitors elbasvir and grazoprevir and HIV protease inhibitors ritonavir, atazanavir, lopinavir, or darunavir in healthy participants. Antimicrob Agents Chemother. 2019;63(4):e02142-18.

16. Mogalian E, Stamm LM, Osinsusi A, Brainard DM, Shen G, Ling KHJ, et al. Drug–drug interaction studies between hepatitis C virus antivirals sofosbuvir/velpatasvir and boosted and unboosted human immunodeficiency virus antiretroviral regimens in healthy volunteers. Clin Infect Dis. 2018;67(6):934–40.

17. Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry-Roguet V, Tamatei C, et al. Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety. Br J Clin Pharmacol. 2018;84(2):404–9.

18. Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr. 2016;71(5):530–7.

19. Feng HP, Guo Z, Ross LL, Fraser I, Panebianco D, James P, et al. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019;74(3):710–7.

20. Smolders EJ, Pape S, de Kanter CT, van den Berg AP, Drenth JP, Burger DM. Decreased tacrolimus plasma concentrations during
HCV therapy: a drug–drug interaction or is there an alternative explanation? Int J Antimicrob Agents. 2019;49(3):379–82.

34. Smolders EJ, Ter Horst PJG, Wolters S, Burger DM. Cardiovascular risk management and hepatitis C: combining drugs.Clin Pharmacokinet. 2019;58(5):565–92.

35. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure EJ, Ter Horst PJG, Wolters S, Burger DM. Cardiovascular risk management and hepatitis C: combining drugs. Clin Pharmacokinet. 2019;58(5):565–92.

36. Regan CP, Morissette P, Regan HK, Travis JJ, Gerenser P, Wen J, et al. Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys. Hepatology. 2016;64(5):1340–41.

37. FDA Drug Safety Communication. FDA warns of serious slowing of the heart rate when the antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) of Sovaldi in combination with another direct acting antiviral drug. 2015. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM439492.pdf.

38. Caldeira D, Rodrigues FB, Duarte MM, Sterrantino C, Barra M, Goncalves N, et al. Cardiac harms of sofosbuvir: systematic review and meta-analysis. Drug Saf. 2018;41(1):77–86.

39. van Seyen M, Smolders EJ, van Wijngaarden P, Drenth JPH, European Commission. Commission staff working document E. J. Smolders et al. PanACEA (Pan-African Consortium for the Evaluation of Antituberculosis Antibiotics). 2019. http://panacea-tb.net/. Accessed 19 Mar 2019.

40. Centers for Disease Control and Prevention. Treatment for TB disease. 2019. https://www.cdc.gov/tb/topic/treatment/tb disease.htm. Accessed 19 Mar 2019.

41. Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, et al. Preclinical pharmacokinetics and first-in-human pharmacokinetics, safety, and tolerability of velpatasvir, a pangenotypic hepatitis C virus NS5A inhibitor, in healthy subjects. Antimicrob Agents Chemother. 2017;61(5):e02084-16.

42. European Commission. Commission staff working document on combatting HIV/AIDS, viral hepatitis and tuberculosis in the European Union and neighbouring countries—state of play, policy instruments and good practices. 2018. https://ec.europa.eu/health/sites/health/files/communicable_diseases/docs/swd_2018_387_en.pdf. Accessed 19 Mar 2019.

43. Caldeira D, Rodrigues FB, Duarte MM, Sterrantino C, Barra M, Goncalves N, et al. Cardiac harms of sofosbuvir: systematic review and meta-analysis. Drug Saf. 2018;41(1):77–86.

44. van Seyen M, Smolders EJ, van Wijngaarden P, Drenth JPH, Wouthuizen-Bakker M, de Knecht RJ, et al. Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. J Hepatol. 2019;70(3):552–4.

45. European Commission. Commission staff working document on combatting HIV/AIDS, viral hepatitis and tuberculosis in the European Union and neighbouring countries—state of play, policy instruments and good practices. 2018. https://ec.europa.eu/health/sites/health/files/communicable_diseases/docs/swd_2018_387_en.pdf. Accessed 19 Mar 2019.

46. Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018;47(5):674–9.

47. Kwo P, Fried MW, Reddy KR, Soldevilla-Pico C, Khemichian S, Darling J, et al. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. Hepatol Commun. 2018;24(4):354–63.

48. Poodad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505.

49. Rockstroh JK, Inglizl P, Petersen J, Peck-Radosavljevic M, Welzel TM, Van der Valk M, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease. Antivir Ther. 2017;22(3):225–36.

50. Wilson E, Kattakuzhy S, Kwo P, Davitkov P, Qureshi K, Sundaram V, et al. Real-world effectiveness of 8 and 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in Blacks with HCV: a comparative analysis of clinical trials with real world cohorts. AASLD: The Liver Meeting; 20–24 Oct 2017; Washington, DC.

51. Buggisch P, Vermehren J, Mauss S, Gunther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2012;57(1):24–31.

52. Wilson E, Kattakuzhy S, Kwo P, Davitkov P, Qureshi K, Sundaram V, et al. Real-world effectiveness of 8 and 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in Blacks with HCV: a comparative analysis of clinical trials with real world cohorts. AASLD: The Liver Meeting; 20–24 Oct 2017; Washington, DC.

53. Buggisch P, Vermehren J, Mauss S, Gunther R, Schott E, Pathil A, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol. 2012;57(1):24–31.

54. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63(5):1493–505.

55. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2013;370(20):1889–98.

56. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–93.
64. Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.

65. Kohli A, Kapoor R, Sims Z, Nelson A, Sidhatharan S, Lam B, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15(9):1049–54.

66. Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64(4):1049–56.

67. Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16(4):459–64.

68. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454–1461.e1.

69. Ueda Y, Ikegami T, Akamatsu N, Sawayama A, Shinoda M, Goto R, et al. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience. J Gastroenterol. 2015;52(8):986–91.

70. Liu CJ, Chuang WL, Sheen IS, Wang HY, Chen CY, Tseng KC, et al. Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV. Gastroenterology. 2018;154(4):989–97.

71. Lim YS, Ahn SH, Lee KS, Paik SW, Lee YJ, Jeong SH, et al. A phase IbII study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. Hepatol Int. 2016;10(6):947–55.

72. Yeh WW, Fraser IP, James P, Petry A, Lepeleire I, Robberechts M, et al. Antiviral activity, safety, and tolerability of multiple ascending doses of elbasvir or grazoprevir in participants infected with hepatitis C virus genotype-1 or -3. Clin Ther. 2018;40(5):704–718.e6.

73. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Gueder D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075–86.

74. Wei L, Jia JD, Wang FS, Niu JQ, Zhao XM, Mu S, et al. Efficacy and safety of elbasvir/grazoprevir in participants with HCV genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: final results from the randomized C-CORAL study. J Gastroenterol Hepatol. 2019;34(1):12–21.

75. Jacobson IM, Lawitz E, Kwo PY, Hezode C, Peng CY, Howe AYM, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology. 2017;152(6):1372–1382.e2.

76. Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–72.

77. Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, et al. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat. 2017;24(10):895–9.

78. Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: a randomized trial. Hepatology. 2018;67(6):2113–26.

79. de Ledinghen V, Lafortest C, Hezode C, Pol S, Renaud A, Alric L, et al. Treatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 previously failed a NS5A- or NS3-containing regimen: the ANRS HC34 REVENGE study. Clin Infect Dis. 2018;66(7):1013–8.

80. Lawitz E, Freilich B, Link J, German P, Ho Han L, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22(12):1011–9.

81. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruenewald N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.

82. Foster GR, Afshald N, Roberts SK, Braun N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.

83. Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, et al. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther. 2018;47(12):1690–8.

84. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):818–26.

85. Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman CAM, Davis MN, et al. Sofosbuvir-velpatasvir for hepatitis C virus infection: a randomized study. Hepatology. 2017;66(4):1083–9.

86. Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, et al. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):809–17.

87. Curry MP, O'Leary JG, Bzowej N, Kirton BL, Kamel JM, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28.

88. Takehara T, Sakamoto N, Nishiguchi S, Ikeda F, Takeuchi T, Ueno Y, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54(1):87–95.

89. Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, et al. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day monotherapy for hepatitis C virus genotype 1 infection. Hepatology. 2017;66(1):263–71.

90. Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir for chronic hepatitis C virus infection: a randomized trial. Ann Intern Med. 2017;166(3):272–82.

91. Han SY, Hwang RG, Thuluvath PJ, et al. Sofosbuvir with velpatasvir in treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol. 2015;63(3):564–72.

92. Forns X, Lee SS, Ballesteros JL, Valdivieso E, Ghalib R, Aguilar H, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–8.
93. Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, et al. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2017. https://doi.org/10.1002/hep.29510 (Epub 2017 Sep 2).

94. Rodriguez-Torres M, Glass S, Hill J, Freilich B, Hassman D, Di Bisceglie AM, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1–4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016;23(8):614–22.

95. Gane EJ, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology. 2016;151(5):902–9.

96. Jacobson IM, Lawitz E, Gane EJ, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown LM, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016;151(3):448–56.e1.

97. Babatin MA, Alghamdi AS, Albenmousa A, Alaseeri A, Aljarodi M, Alblidi H, et al. Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitis C genotype 4 infection. J Clin Gastroenterol. 2018;52(5):452–7.

98. Coilly A, Fougouer-Leurent C, de Ledinghen V, Houssell-Debry P, Duvox C, Di Martino V, ANRS C023 CUPILIT study group, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence—the ANRS CUPILIT study. J Hepatol. 2016;65(4):711–8.

99. Hezode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, et al. Daclatasvir plus sofosbuvir, with or without ritavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int. 2017;37(9):1314–24.

100. Grebely J, Dore GJ, Zeuzem S, Apstein RJ, Fox R, Han L, et al. Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: analysis of phase 3 ASTRAL trials. Clin Infect Dis. 2016;63(11):1479–81.

101. von Felden J, Vermehren J, Inglizil P, Mauss S, Tutt R, Simon KG, et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2018;47(9):1288–95.

102. Wyles D, Brau N, Kotttilil S, Daar ES, Ruane PJ, Workowski K, et al. Sofosbuvir and velpatasvir for the treatment of hepatitis C virus in patients coinfected with human immunodeficiency virus type 1: an open-label, phase 3 study. Clin Infect Dis. 2017;65(1):6–12.

103. Esteban R, Pineda JA, Calleja JL, Casado M, Rodriguez M, Turnes J, et al. Efficacy of sofosbuvir and velpatasvir, with and without ritavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155(4):1120–1127.e4.

104. Agarwal K, Castells L, Mullhaupt B, Rosenberg WMC, McNabb B, Arterburn S, et al. Sofosbuvir for 12 weeks in genotype 1–4 HCV-infected liver transplant recipients. J Hepatol. 2018;69(3):603–7.

105. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, Brown A, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448–55.

106. Kumada H, Watanabe T, Suzuki F, Ikeda K, Sato K, Toyoda H, et al. Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53(4):566–75.

107. Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2017. https://doi.org/10.1002/hep.29541 (Epub 2017 Sep 19).

108. Gane EJ, Schwabe C, Hyland RH, Yang Y, Svarovsky E, Stamm LM, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with hepatitis C virus genotype 1 or 3 infections. Gastroenterology. 2016;151(3):448–56.e1.
123. Sułkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1087–97.

124. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised phase 2 trial. Lancet Infect Dis. 2016;16(6):685–97.

125. Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WI, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–13.

126. Tam E, Luukenemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, et al. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: findings from two randomized trials. Liver Int. 2018;38(6):1010–21.

127. Rockstroh JK, Bhagani S, Hyland RH, Mathurin P, et al. Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. Lancet Gastroenterol Hepatol. 2017;2(5):347–53.

128. Braun DL, Hampel B, Kouyos R, Nguyen H, Shah C, Flepp M, et al. High cure rates with grazoprevir-elbasvir with or without ribavirin guided by genotype resistance testing among human immunodeficiency virus/hepatitis C virus-coinfected men who have sex with men. Clin Infect Dis. 2019;68(4):569–76.

129. Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, et al. The safety and effectiveness of ledipasvir-sofosbuvir in Taiwanese patients with chronic genotype 1 hepatitis C virus infection. J Gastroenterol. 2014;52(4):520–33.

130. Smolders EJ, de Kanter CT, van Hoek B, Arends JE, Drenth JP, et al. Efficacy and decompensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79–86.

131. Reddy KR, Bourliere M, Sułkowski M, Omata M, Zeuzem S, Feld JJ, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397–404.

132. Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, et al. Safety and effectiveness of ledipasvir and sofosbuvir, with or without ribavirin, in treatment-experienced patients with genotype 1 hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2018;16(11):1811–1819.e4.

133. Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shakwak M, Yousif S, Ullah W, et al. Treatment of patients with hepatitis C virus infection with ledipasvir-sofosbuvir in the liver transplant setting. Transplantation. 2017;101(11):2739–45.

134. Modr AA, Nazario HE, Gonzales GR, Gonzalez SA. Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Aliment Pharmacol Ther. 2018;47(10):1409–15.

135. Marshall WL, Feng HP, Wenning L, Garrett G, Huang X, Liu F, et al. Pharmacokinetics, safety, and tolerability of single-dose elbasvir in patients with hepatic impairment. Eur J Drug Metab Pharmacokinet. 2018;43(3):321–9.

136. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Mounour H Jr, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–45.

137. Mogalian E, Mathias A, Brainard D, McNally J, Moorehead L, Hernandez M, et al. The pharmacokinetics of GS-5816, a pan-genotypic HCV NS5A inhibitor, in HCV-uninfected subjects with moderate and severe hepatic impairment. J Hepatol. 2014;60(1):S317.
PK and PD Considerations in Viral Hepatitis C Therapy

179. Nagao A, Hanabusa H. Brief report: the impact of ledipasvir/sofosbuvir on HIV-positive and HIV-negative Japanese hemophilia patients with 1, 4, and mixed-genotype HCV. J Acquir Immune Defic Syndr. 2017;74(4):418–22.

180. Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazolla V, et al. Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Aliment Pharmacol Ther. 2017;46(4):424–31.

181. Moon J, Hyland RH, Zhang F, Brainard DM, Lanzkron S, Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazolla V, et al. Ledipasvir and sofosbuvir for the treatment of chronic hepatitis C in persons with sickle cell disease. Clin Infect Dis. 2017;65(5):864–6.

182. American Association for the Study of Liver Diseases (AASLD). HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2018. https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/HCVGuidance_May_24_2018b.pdf. Accessed 19 Mar 2019.

183. Squires JE, Balistreri WF. Hepatitis C virus infection in children and adolescents. Hepatol Commun. 2017;1(2):87–98.

184. Bernstein HB, Dunkelberg JC, Leslie KK. Hepatitis C in pregnancy in the era of direct-acting antiviral treatment: potential benefits of universal screening and antepartum therapy. Clin Obstet Gynecol. 2018;61(1):146–56.

185. El-Karaksy H, Mogahed EA, Abbasse A, Ghobrial C, El-Raziky MS, El-Koofy N, et al. Sustained viral response in genotype 4 chronic hepatitis C virus-infected children and adolescents treated with sofosbuvir/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67(5):626–30.

186. Yakoot M, El-Shabrawi MH, AbdElGawad MM, Mahfouz AA, Helmy S, Abdo AM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr. 2018;67(1):86–9.

187. Abdel Ghaffar TY, El Naghib S, Abdel Gawad M, Helmy S, Abdel Ghaffar A, Yousef M, et al. Safety and efficacy of combined sofosbuvir/daclatasvir treatment of children and adolescents with chronic hepatitis C genotype 4. J Viral Hepat. 2019;26(2):263–70.

188. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5b non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736–743.e1.

189. Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, et al. Efficacy and safety of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic HCV genotype 1 infection receiving opioid substitution therapy: analysis of phase 3 ION trials. Clin Infect Dis. 2016;63(11):1405–11.

190. Johnson SW, Ammirati SR, Hartis CE, Weber SF, Morgan MR, Darnell TA, et al. Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach. Int J Antimicrob Agents. 2017;49(6):778–81.

191. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LON-ESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–23.

192. Suda G, Ogawa K, Yamamoto Y, Katagiri M, Furuya K, Kumagai K, et al. Retreatment with sofosbuvir, ledipasvir, and addition of ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. J Gastroenterol. 2017;52(10):1122–9.

193. Wyles D, Pockros P, Morelli G, Younes Z, Svarovskaia E, Yang JC, et al. Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens. Hepatology. 2015;61(6):1793–7.

194. Kowdle KY, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–88.

195. Zeng QL, Xu GH, Zhang JY, Li W, Zhang DW, Li ZQ, et al. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study. J Hepatol. 2017;66(6):1123–9.

196. Gane EJ, Hyland RH, Yang Y, Svarovskaia E, Stamm LM, Brainard DM, et al. Efficacy of ledipasvir plus sofosbuvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2 infection. Gastroenterology. 2017;152(6):1366–71.

197. Brown A, Hezode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, et al. Efficacy and safety of 12 weeks of elbasvir plus grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: the C-SCAPE study. J Viral Hepat. 2018;25(5):457–64.

198. Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouda MHA, Salama MM, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol. 2018;2018:9616234.

199. Ahmed OA, Kaisar HH, Badawi R, Hawash N, Samir H, Shabana SS, et al. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist. 2018;11:295–8.

200. Shiha G, Esigmat G, Hassany M, Soliman R, Elbasyony M, Fouda R, et al. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut. 2019;68(4):721–8. https://doi.org/10.1136/gutjnl-2017-315906.

201. Elbaz T, Abdo M, Omar H, Hassan EA, Zaghoul AM, Abdelsamie M, et al. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. J Med Virol. 2019;91(2):272–7.

202. Grebely J, Dalgard O, Conway B, Cunningham EB, Bruggmann P, Hajarizadeh B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018;3(3):153–61.

203. Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hezode C, et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2018;67(4):1253–60.

204. Pott-Junior H, Bricks G, Grandi G, Figueiredo Senise J, Castelo Filho A. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. Clin Microbiol Infect. 2019;25(3):365–71.

205. Chu X, Liao M, Shen H, Yoshida K, Zur AA, Arya V, et al. Clinical probes and endogenous biomarkers as substrates for transporter drug–drug interaction evaluation: perspectives from the international transporter consortium. Clin Pharmacol Ther. 2018;104(5):836–44.